Y-mAbs Therapeutics Q4 2023 Earnings Report

Y-mAbs Therapeutics EPS Results

• Actual EPS: -$0.02
• Consensus EPS: -$0.19
• Beat/Miss: Beat by +$0.17
• One Year Ago EPS: N/A

Y-mAbs Therapeutics Revenue Results

• Actual Revenue: $23.36 million
• Expected Revenue: $21.72 million
• Beat/Miss: Beat by +$1.64 million
• YoY Revenue Growth: N/A

Y-mAbs Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 2/29/2024
• Time: N/A

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.